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Abstract 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not the use 
of probiotics treat abdominal pain in children between the ages of 4 and 18 with irritable bowel 
syndrome. 
 
STUDY DESIGN: Systemic review of three randomized controlled trials (RCTs) published after 
2007, all English language. 
 
DATA SOURCES: All three randomized controlled trials were found on PubMed and were 
selected based on relevance to the proposed clinical question.  
 
OUTCOMES MEASURED: Main outcomes measured were duration with and without 
abdominal pain, severity of pain, postprandial swelling, belching-abdominal distention, difficulty 
in defecation, urgent defecation, and feeling of incomplete defecation. Outcomes were measured 
by using Wonger-Baker FACES pain rating scale, five-point likert scale, and a self-reported 
questionnaire.  
 
RESULTS:  Two studies found no significant improvement in abdominal pain or discomfort 
when comparing probiotics to placebo when treating irritable bowel syndrome. One study found 
a significant improvement in abdominal pain when comparing probiotics to placebo. When 
looking at efficacy of probiotics, two studies had a relatively low number needed to treat.  
 
CONCLUSION: From the three randomized controlled trials, it can be concluded that treating 
children with irritable bowel syndrome between the age of 4 and 16 with probiotics is 
inconclusive. Further research is warranted.  
 
KEY WORDS: Irritable bowel syndrome and probiotics 
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INTRODUCTION:  
Irritable bowel syndrome, according to Rome III criteria, is defined as abdominal pain or 
discomfort associated with relief after defecation, change in stool frequency and/or a change in 
stool consistence.1 According to the National Institute of Diabetes and Digestive and Kidney 
Disease, IBS is diagnosed when a child, who is growing as expected, has abdominal pain or 
discomfort once per week for at least 2 months without other disease or injury that could explain 
the pain.2 IBS has varying symptoms including cramping, bloating, diarrhea, constipation, or 
alternating diarrhea and constipation. IBS is not life-threating but can impact daily activities and 
quality of life.3 
Irritable bowel syndrome is the most common gastrointestinal diagnosis among 
gastroenterology practices in the United States.2 It is also one of the top 10 reasons patients visit 
their primary care physician.2 According to reported studies, the disease prevalence is lower in 
the Hispanic, Asian and black population.3 In a pediatric population, males and females are 
equally affected.3 IBS symptoms are reported in 14% of high-school students and 6% of middle-
school students.3 Irritable bowel syndrome is not described in preschool-aged or in younger 
children because the diagnosis depends on the child’s ability to report detailed symptoms.3 
Children who have a history of recurrent abdominal pain are at increased risk of developing IBS 
in the future.2  
Due to high prevalence of this condition, there is a definite economic burden in the 
United States. The exact number of pediatric visits per year is unknown but in the general 
population there are between 2.4 and 3.5 million annual visits.3,4 Not all individuals with IBS 
symptoms obtain medical care.4 Most physicians diagnose IBS using diagnosis of exclusion 
because there are no diagnostic studies available. Using this method to diagnose IBS leads to 
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extensive and unnecessary testing.5 The direct cost for the general population has been estimated 
to range from $1.5 to $10 billion per year.5 These figures do not take into account prescriptions 
and over-the counter medications which can further increase the expenditure. The indirect cost of 
IBS has been estimated to be much greater, approaching $20 billion per year.5  
The cause of IBS is unknown. Researchers believe a combination of physical and 
abnormal psychotic disorders can lead to irritable bowel syndrome.2 Possible causes of IBS in 
children include signal disruption between the brain and GI tract, abnormal GI motility, 
hypersensitivity to abdominal pain, anxiety, depression, bacterial gastroenteritis, small intestinal 
bacterial overgrowth, and genetics.2   
 Irritable bowel syndrome is not a disease; it is a group of symptoms that occur together.2 
Unfortunately there is no cure for IBS. Treatment is based on symptoms patients are 
experiencing. Symptoms can be treated with dietary changes, medication, probiotics, and 
therapy.2 Medications commonly used include fiber supplements, laxatives, antidiarrheals, 
antispasmodics, and antidepressants. Cognitive behavioral therapy, psychodynamic/interpersonal 
therapy, and hypnotherapy can help reduce stress and improve IBS symptoms.2  
Probiotics have multiple beneficial effects in the gastrointestinal tract, such as increasing 
the mass of bacterial microflora, decreasing bacterial overgrowth, inducing the intestinal 
mucosal barrier, and normalizing the motility of the digestive tract.6 Also, they can regulate the 
balance between the pro- and anti-inflammatory cytokines.6 Due to these beneficial effects, 
probiotics have been suggested as a therapeutic option for IBS.6 Studies have found that 
probiotics, specifically Bifidobacteria and certain probiotic combinations, improve symptoms of 
IBS when taken in large amounts.2 
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OBJECTIVE:  
The objective of this selective EBM review is to determine whether or not the use of 
probiotics treat abdominal pain in children between the ages of 4 and 18 with irritable bowel 
syndrome. 
METHODS 
 Three double-blind randomized controlled trials (RCTs) were used in this review. The 
population studied included patients between the ages of 4 and 18 with irritable bowel syndrome. 
The intervention used in all three RCTs was probiotics. The populations were compared to a 
control group who were given a placebo. Outcomes measured in the study included abdominal 
pain and abdominal discomfort.  
“Irritable bowel syndrome” and “probiotics” were keywords used to narrow the search on 
PubMed. All articles were published in English and in peer-reviewed journals. Articles were 
selected by relevance to the clinical question and had patient oriented results (POEM). Studies 
that were POEM’s, randomized controlled trials, and published after 2007 were included. 
Cochrane systemic reviews, meta-analysis’s, and patients over the age of 18 were excluded. 
Statistics used were relative risk reduction (RRR), absolute risk reduction (ARR), numbers 
needed to treat (NNT), p-value, and mean change from baseline. Table 1 demonstrates the 
demographics and characteristics of the reviewed studies.  
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Table 1: Demographics and characteristics of included studies  
Study Type #pts Age 
(yrs.) 
Inclusion criteria Exclusion criteria W/D Interventions 
Basturk7 
(2016) 
RCT 71 4-16 Patients who 
were diagnosed 
with IBS 
according to the 
Rome III criteria 
in the Akdeniz 
University 
Pediatric 
Gastroenterology 
outpatient clinic 
between 
September 2014-
May 2015. 
Patients who are 
not diagnosed with 
IBS. 
5 Probiotic 
treatment (5 
x 109 CFU B. 
Lactis) BID 
PO x 4 
weeks. 
Jadresin1 
(2016) 
RCT 55 4-18 Patients who 
were diagnosed 
with functional 
abdominal pain 
and IBS at the 
children’s 
hospital Zagreg 
from May 2012-
December 2014 
Patients with 
underlying 
diseases or has 
been treated with 
an 
antibiotic/probiotic 
7 days prior to 
enrollment. 
9 Probiotic: 
citrus 
flavored 
450mg 
chewable 
tablet qd x 
12 weeks. 
The total 
value count 
of L. reuteri 
was 1 x 
108live 
bacteria 
(CFU)/tablet 
Kianifar6 
(2015) 
RCT 60 4-18 Patients who 
were diagnosed 
with IBS by a 
pediatric 
gastroenterologist 
and have had 
active symptoms 
of abdominal 
pain for at least 2 
weeks prior to 
the start of the 
study. 
Patients with 
underlying 
diseases or taking 
any medications 
8 Probiotic 
capsule that 
contained 
LGG at a 
concentration 
of 1x 1010 
cfu/ml 
bacteria and 
inulin. BID x 
4 weeks. 
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OUTCOMES MEASURED  
The Basturk et al study, evaluated outcomes such as postprandial swelling, belching-
abdominal distention, difficulty in defecation, urgent defecation, and feeling of incomplete 
defecation. A self-reported questionnaire was used prior to treatment and post treatment. Patients 
with improvement in all presenting symptoms were accepted as ‘fully benefited’ and those who 
had resolution in one or several symptoms were accepted as ‘partially benefited’.1 
The outcome from Kianifar et al, study evaluated severity of pain. A five-Likert scale 
was used to specify the severity of the pain (0=very mild, 1= mild, 2= moderate, 3= severe, 4= 
very severe).6 From both groups, outcomes were measured (placebo and probiotic) prior to 
treatment and weekly for four weeks. Intervention lasted for four weeks.  
Patients in the Jadresein et al study were given a diary to rate severity of pain on a daily 
basis. The probiotic and placebo were discontinued after twelve weeks but rating severity of pain 
daily continued for another four weeks. Even though patients were asked to record daily, they 
were required to visit a certain hospital for evaluation on month one, three, and four. Symptoms 
were evaluated using a faces scale (Wong-Baker FACES Pain Rating Scale; 0-no hurt-10 hurts 
worst) for pain.1 
RESULTS 
 Basturk et al study, included children between the ages of 4 and 16 years who were 
diagnosed with IBS according to the Rome III criteria in the Akdeniz University Pediatric 
Gastroenterology outpatient clinic between September 2014 and May 2015.7 The study did not 
report an exclusion criteria for selecting patients.  Family members of each patient disclosed a 
written informed consent. Trial was double-blinded; forty-eight patients were randomized into an 
experimental and control group. The experimental group which consisted of twenty-four patients 
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received a probiotic (5x109 CFU B. lactis) twice a day for four weeks. The control group which 
had twenty-four patients were given a placebo (900mg of inulin) twice a day for four weeks. 
Self-reported questionnaires were used to evaluate the efficacy of probiotics in treating IBS.  
Initially, there was no significant difference in symptoms between both groups.7 Chi-square test 
was used to analyze the collected data from the self-reported questionnaire. In the probiotic 
group, the most significant improvement observed was belching-abdominal fullness (p<0.001), 
while there were also significant improvements in bloating after meals (p=0.016), and difficulty 
with defecation (p=0.031).7 Full recovery was observed in seven patients (29.2%) in the 
probiotic group and three patients in the placebo group (12.5%).7 When the groups were 
compared with each other with regards to full recovery, there were no significant difference 
between the prebiotics and probiotics, p= 0.155.7  Table 2 demonstrates the statistical 
significance between both groups. Data demonstrated relative risk reduction of 45% and absolute 
risk reduction of 21%. NNT is -4. NNT, numbers needed to treat, means for every 4 children 
treated with probiotics it would prevent one fewer child from experiencing excruciating 
abdominal pain, compared to the control group.  
Table 2: Statistical significance at baseline and 4 weeks, belching-abdominal fullness 
 Before After p-value 
Probiotics 
(n-24) 
75% 25% <0.001* 
Placebo 
(n=24) 
54.2% 45.8% 0.250 
 Chi-square test was used.  
*p-value £ 0.05 is significant 
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Table 3: Efficacy of Basturk et al7 study. 
% of participants, 
within the comparison 
group, who experienced 
belching-abdominal full 
after 4 weeks (CER) 
% of participants, 
within interventional 
group, who experienced 
belching-abdominal full 
after 4 weeks (EER) 
Relative 
risk 
reduction 
(RRR) 
Absolute 
risk  
reduction 
(ARR) 
Numbers needed to 
harm (NNT) 
45.8% 25% 45% 21% -4 patients 
 
In the Kianifar et al study, the inclusion criteria were patients age 4 to 18 years old who 
had active symptoms of abdominal pain for at least two weeks before the beginning of the study 
and had been diagnosed with IBS by a pediatric gastroenterologist.6 The diagnosis must have 
been made on the basis of Rome III criteria and other differential diagnosis must have been 
excluded by laboratory evaluation, abdominal ultrasound, radiographic imaging, endoscopy, and 
breath hydrogen testing.6 Patients who are currently taking drugs or had an underlying disease 
such as cardiac disease, renal disease, asthma, failure to thrive, cystic fibrosis were excluded.6 
Sixty patients were initially selected however eight patients who were initially included were 
excluded due to lack of follow up or due to a rise of another illness. Fifty-two participants were 
randomly assigned to a control or interventional group. Twenty-six participants received a 
probiotic (LGG 1x1010) twice per day for four weeks. Twenty-six participants received a placebo 
(inulin) twice per day for four weeks. Patients were evaluated weekly with using the five-point 
likert scale to specify severity of pain. Although no significant difference was obtained regarding 
the baseline pain severity scales between the two groups, a statistically difference was observed 
from one week after treatment.6 The p-value one week after treatment was <0.01. Data was 
continuous and not convertible to a dichotomous format. Outcomes were measured before 
intervention and weekly for four weeks in each group. Wilcoxan rank-sum test was used to 
compare changes in abdominal pain (Table 4).  
                                                                                                        Gonzalez, IBS, & Probiotics  8 
Table 4: Pain severity before intervention and weekly for 4 weeks.  
 Pre-treatment 1week after 
Treatment 
2 weeks after 
treatment 
3 weeks after 
treatment 
4 weeks 
after 
treatment 
Probiotic 2.5 ± 0.9 1.5±1.0 1.2±1.1 1.0±0.9 0.8±0.9 
Inulin 
(Placebo) 
2.7±0.8 1.8±0.6 1.9±0.8 1.8±0.6 1.5±0.8 
P-value 0.4 0.01 0.00 0.00 0.00 
 
In the Jadresin et al study, the inclusion criteria were children between age 4 and 18 years 
old who had been diagnosed with IBS at the Children’s Hospital Zagreb from May 2012 to 
December 2014.1 Patients who had a known or suspected immunodeficiency, treated with 
probiotics and/or prebiotics seven days prior to enrollment, known neoplastic disorder, or any 
other chronic disease were excluded.1 Written informed consent was obtained from the parent or 
guardian of each child in the study as well as from children if older than nine years.1 Once 
patients were randomized, they were asked to report back to the hospital monthly.1 Intervention 
lasted twelve weeks and patients were followed four weeks after intervention.1  Children who 
were non-compliant to treatment were excluded.1 Data was analyzed for fifty-five participants, 
twenty-six received a probiotic (450mg L. reuteri 1x108) daily and twenty-nine received a 
placebo daily. There was a difference between both groups in the number of days without pain, 
with the median of 89.5 (range 5-108) days in the experimental group and 51 (range 0-107) days 
in the placebo group (p=0.029).1 Participants taking the probiotic or inulin experienced 
significant reduction in severity of abdominal pain from first to fourth month, although reduction 
was more prominent in the experimental (probiotic) group (p<0.001 vs p=0.004) (table 5).1  No 
adverse effects were reported. There was no significant differences in number of participants 
with complete resolution of abdominal pain between probiotic and inulin group.1 Complete 
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resolution of abdominal pain until the end of treatment (16 weeks) was seen in 16 
(61.5%) participants from active group and 16 (55.2%) participants from placebo group 
(p=0.633) (table 6).1 All patients, including the patients who discontinued the intervention, were 
followed up until the end of the study; they were included into intention to treat analysis.1 Data 
demonstrated relative benefit increase of 0.11% and absolute benefit increase 6.3%. NNT was 
16. For every 16 children treated with probiotics it would prevent one fewer child from suffering 
abdominal discomfort, comparted to the control group.  
Table 5: Comparing severity of pain between beginning and end of treatment. 
 Severity of 
abdominal pain per 
day in 1st month, 
median (range) 
Severity of 
abdominal pain per 
day in 4th month, 
median (range) 
P 
Probiotics (active) 0.75 (0-2.9) 0.21 (0-1.7) <0.001 
Inulin (placebo) 0.96 (0.3-2.8) 0.6 (0-2) 0.004 
Assessed by Wong-Baker FACES Pain Rating Scale per group (Wilcoxon test) 
Table 6: Efficacy of Jadresin et al study 
Resolution of abdominal 
pain abdominal pain in 
the control group 
(placebo) 
(CER) 
Resolution of abdominal 
pain in the experiment 
group (probiotics) 
(EER) 
Relative 
benefit  
Increase 
(RBI) 
Absolute 
benefit  
Increase 
(ABI) 
Numbers needed to 
treat (NNT) 
55.2% 61.5% 0.11% 6.3% 16 
 
Safe and Tolerability 
 In all three-randomized control trials no adverse events were reported in neither group. 
Probiotics were well tolerated. Patients experiencing active IBS symptoms such as constipation, 
diarrhea, or bloating probiotics did not aggregate or increase reoccurrence of IBS symptoms.  
DISCUSSION  
 Irritable bowel syndrome is a condition that presents with various signs and symptoms. 
The main cause of IBS is inconclusive; however, it is recognized to be multifactorial. The 
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approach to managing irritable bowel syndrome is reducing the reoccurrence of gastrointestinal 
pain and discomfort. Non-pharmaceutical and pharmaceutical therapies may be implemented 
such as change in diet, exercising, counseling, medications.  
Studies have been performed to determine the effectiveness of using probiotics to treat 
IBS but in the adult population. It is challenging to conduct trials in the pediatric population 
because there are more regulations such as receiving approval of the participants guardian. In the 
pediatric population, few studies have been done and results are inconclusive.  Kianifar et al 
study, faced some limitations such as small sample size, short duration of treatment, and not 
following up after cessation of treatment.6 Basturk et al study found probiotics effective in 
children who have been diagnosed with IBS.7 However, a major limitation in the study was that 
it was done in a tertiary health care center which meant dealing with relatively more complex 
participants.7 Jadresin et al,study consisted of a small sample size. In future studies, long-term 
treatment and long-term follow up can help evaluate the efficiency of probiotics. It is suggested 
to conduct studies that include a large sample size, exclude patients who don’t have a history of 
an underlying disease, and involve children from the general population to increase 
generalizability.  
CONCLUSION  
Based on these three studies, probiotics can treat abdominal pain in children between the 
ages of 4 & 18 with Irritable bowel syndrome. However, future research is warranted. Some ideas 
to consider is involving children from general population to increase generalizability, have a larger 
sample size, extend duration of study, and following up after cessation of treatment. Other items 
to consider is determining if combination therapy is more effective than monotherapy.  
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In the pediatric population, probiotics are being used to treat IBS. However, there has not 
been significant research to prove that it has been effective.  
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